Skip to content Skip to footer
Subscribe Now

NEWS

Hims & Hers Launches Multi-Cancer Blood Test by Galleri
Shots: Hims & Hers Health has launched access to the Multi-Cancer Test by Galleri, offering a simple blood test for early cancer screening The Hims & Hers Multi-Cancer Test by Galleri detects a shared signal from 50+ cancers, incl. those without recommended screenings, & can be taken annually to help identify cancers early, often before…
February 5, 2026
Evogene and Shanghai Lishan Biopharmaceuticals Partner for BMC128
Shots: Biomica (Evogene’s subsidiary) & Shanghai Lishan Biopharmaceuticals have entered into an exclusive worldwide licensing agreement for BMC128, currently in P-I trial As per the deal, Lishan Biotech will receive exclusive rights to develop, manufacture, & commercialize BMC128, with Biomica receiving development milestone payments & royalties on future commercial sales Lishan Biotech is planning to…
February 5, 2026
Alvotech Reveals PK Data on AVT80 (Biosimilar, Entyvio)
Shots: Alvotech reported positive top-line data from the AVT80-GL-P01 PK study comparing AVT80 with Entyvio in healthy adults The study met all 1EP, demonstrating PK similarity between AVT80 & Entyvio following a single 108mg/0.68mL SC dose, supporting AVT80’s biosimilar profile Alvotech is developing AVT16 (IV) & AVT80 (SC) as Entyvio’s biosimilars, with the AVT80-GL-P01 study…
February 5, 2026
ZipBio and MeiraGTx Partner to Advance AAV Gene Therapy for Geographic Atrophy
Shots: ZipBio has entered into an exclusive license agreement with MeiraGTx, granting MeiraGTx exclusive right to AAV gene therapy to treat Geographic Atrophy Licensing deal will combine MeiraGTx’s expertise in vector design, clinical development, & in-house genetic medicine manufacturing with ZipBio’s de novo protein therapeutics created using its COMPACT generative AI platform As per the…
February 4, 2026
Relay Therapeutics’ Zovegalisib Receives the US FDA Breakthrough Therapy Designation for PIK3CA-Mutant Advanced Breast Cancer
Shots: The US FDA has granted BTD to zovegalisib + fulvestrant for the treatment of adults with PIK3CA mutant, HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor Designation was supported by P-I/II (ReDiscover) trial data of zovegalisib + fulvestrant ± CDK inhibitors, showing activity…
February 4, 2026
Load more